Danone BN.PA
Danone is a world-class health-focused food company trading at trough multiples and a 1.5x P/E discount to Nestle; rerating to historic levels implies ~€78 vs €48, +62% upside by 2014.
Thesis
Trian argues Danone is a misunderstood world-class consumer staple trading at roughly trough 2003-2012 multiples because the market is over-weighting Southern European exposure and a cyclical yogurt slowdown. In reality Danone already owns the health-and-wellness portfolio (Activia, Evian, Aptamil, medical nutrition) that Nestle and PepsiCo are spending billions to build — Nestle paid 19.8x EBITDA for Pfizer Infant Nutrition — with 52% emerging-market sales, a 23% global yogurt share, and a 15% FCF CAGR since 2007. At €48 the shares yield ~7% FCF and trade at a 1.5x P/E discount to Nestle despite historically commanding a premium. A leaner cost structure, disciplined capital return, and no dilutive M&A should rerate the stock to ~€78 by year-end 2014, a 62% total return.
SCQA
Danone is a €29bn French food leader with a 21st-century health portfolio — 46% yogurt, 37% infant/medical nutrition, 17% water — and 52% emerging-markets sales, among the highest in consumer staples.
Fears over Spain/Italy exposure, yogurt private-label pressure and slowing organic growth have pushed Danone to a ~1.5x P/E discount to Nestle and near-trough 10-year multiples despite fundamentally sound categories and margins.
Management should tighten cost structure, pursue balanced sales-and-EPS growth, avoid dilutive M&A, and let free cash flow fund buybacks — Trian plans constructive engagement rather than a proxy fight.
Rerating to historic and peer levels on normalized 2015 earnings of €4.39 at a 17x forward P/E implies an implied value of ~€78 per share, a +62% total return over a ~2-year holding period.
The three reasons
- 1
Trading near trough multiples with ~7% FCF yield, ~50-60% upside if rerated to Nestle/Unilever
- 2
52% emerging-markets sales — top-tier exposure among consumer staples peers
- 3
Already a pure-play health-and-wellness portfolio that Nestle and Pepsi are paying 20x EBITDA to build
Primary demands
- Push for leaner cost structure to offset European headwinds while preserving R&D and marketing investment
- Adopt balanced approach to driving value: both sales AND EPS growth
- Refrain from dilutive M&A
- Engage management in constructive dialogue
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Heinz (Trian)
- Dr Pepper Snapple (Trian)
- Cadbury (Trian)
- Kraft Foods (Trian)
- Nestle acquisition of Pfizer Infant Nutrition at 19.8x EBITDA
- WhiteWave IPO (Oct 2012) at ~24x 2013 EPS
Notable slides (6)
Notes
Friendly, constructive long thesis presented at the Invest for Kids charity conference — not a proxy campaign. Trian explicitly praises CEO Franck Riboud and frames this as a rerating opportunity rather than a turnaround. Tone is collaborative; thesis leans on multiple_comparison and EM-exposure framing. Uses Nestle (Bulcke) and PepsiCo (Nooyi) CEO quotes to validate the health-and-wellness thesis, not to contradict Danone management. Standout slide is the P/E vs organic-growth correlation chart (p.11) which visualizes Danone as an outlier below the 88% peer regression line. Trian discloses ~1% economic interest.